T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

Researchers have found a reliable way to grow helper T cells from stem cells, solving a major challenge in immune-based ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

CAR T-cell therapy has the potential to revolutionise how we treat certain types of cancer by genetically engineering someone’s own immune cells to attack the disease – but it is also cumbersome and ...

In recent years, cancer treatment has taken a big leap forward with a new, advancement known as CAR T-cell therapy. This may may sound complex, but the idea behind it is fairly simple: using the power ...

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has approved the company’s oncology drug, Nelarabine Injection, ...

In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the immune system's ability to fight against a tumor. Colorectal cancer, however ...